Solara Active Pharma Sciences Ltd

- Solara Active Pharma Sciences is planning a rights issue to raise funds, with board approval for up to INR 450 crores. - The expected amount to be raised is approximately INR 350 to 400 crores, pending finalization based on the reset plan and cash needs. - The rights issue proceeds will primarily be used for debt reduction; no new capital expenditure is planned. - Promoters intend to subscribe to their rights and are willing to underwrite any unsubscribed portion, reflecting confidence in the company's turnaround. - There is no mention of additional debt fundraising beyond this rights issue for now. - The company aims to improve its debt-to-EBITDA ratio to under 3, targeting around 2.5, supported by free cash flow and rights issue proceeds.

- No major new capex planned for the near future as significant new capacities are currently underutilized. - Recurring capex requirement is estimated between INR 40 crores to INR 50 crores per year. - Focus will be on network optimization and capacity utilization rather than new capital investments. - Rights issue proceeds (expected INR 350-400 crores) are primarily aimed at debt reduction, not capex. - Strategic focus includes cost improvements, portfolio maximization, and customer acquisitions rather than capital expenditure. - R&D spend will be sharpened to enhance outcomes and revive dormant DMFs rather than broad, high spending. - Overall approach is to manage existing assets efficiently and improve margins with limited capital expenditure going forward.

- FY '25 revenue guidance is around INR 1,500 crores, roughly flattish compared to FY '24 adjusted for the fire incident. - Focus for the next 4 quarters is primarily on margin expansion rather than aggressive top-line growth. - Growth is expected to resume in H2 FY '25 with new customer acquisitions and new products being seeded. - Historical growth in the last 2 years impacted margins due to network over-utilization; future growth will be more margin-focused. - The company aims for a calibrated, quarter-on-quarter improvement in revenue quality starting Q1 FY '25. - Emphasis on cost improvements, portfolio maximization, and network optimization to enable sustainable volume growth alongside margin expansion.

- Solara expects a reset strategy to double EBITDA by Q4 FY 2025, targeting 20-22% EBITDA margin (Page 6). - Guidance for FY 2025 includes INR 1,500 crores top-line with focus on margin expansion over volume growth initially (Page 7). - Margin expansion of around 500-600 basis points anticipated through cost savings and product mix improvement (Page 7). - EBITDA margin expected to rise from mid-40% to historic 51-52% gross margins gradually over 5 quarters (Page 7). - Free cash generation projected at around INR 150 crores next year, supporting debt reduction and operational efficiency (Page 8). - Management aims for a sustainable return to historical EBITDA levels (~INR 40 crores per quarter) and cautious growth thereafter (Page 6-7). - Growth expected to pick up in H2 FY 2025 after initial focus on margin and operational reset (Page 7).

- The company has a strong order book heading into FY '25 as referenced in the reset strategy. - Production disruptions due to the fire incident in Q3 delayed shipments, but sales shifted to Q4. - Guidance for FY '25 is based on a stronger order book, expected to improve quarterly performance. - They are confident in quality growth and margin expansion driven by this order book. - No explicit numeric value of the current or expected order book was disclosed in the transcript.